

Amendments to the Claims:

Please amend claims 1, 2, 19, 20, 27 and 28 as follows. Please cancel claims 3, 11-26 and 32-45 without prejudice to continued prosecution. The claims and their status are shown below.

1. (Currently Amended) An isolated peptide comprising an amino acid sequence represented by SEQ ID NO[[s]]: 14 [[1-100, 119, 143, 157, 161, 178, 187,]] or a biologically active analog[[s]] thereof that decreases homotypic adhesion among CD66a family members modulate the function of at least one CD66 family member and/or at least one ligand thereof.
2. (Currently Amended) The peptide of claim 1 represented by SEQ ID NO[[s]]: 14 [[1-100, 119, 143, 157, 161, 178, or 187]].
- 3-4. (Canceled)
5. (Previously presented) The peptide of claim 1 which is complexed with a carrier molecule or structure to form a peptide conjugate.
6. (Previously presented) The peptide of claim 5 wherein the carrier molecule or structure is selected from the group of microbeads, liposomes, biological carrier molecules, synthetic polymers, biomaterials, and cells.
7. (Previously presented) The peptide of claim 6 wherein the peptide conjugate binds to cells expressing a CD66 protein or a CD66 ligand.
8. (Previously presented) The peptide of claim 5 wherein the peptide conjugate includes a label.
9. (Previously presented) The peptide of claim 1 which is attached to a label.
10. (Previously presented) The peptide of claim 9 wherein the label is selected from the group consisting of a fluorescent tag, a radioactive tag, a magnetic resonance tag, and enzymatic tag, and combinations thereof.
- 11-18. (Canceled)
19. (Withdrawn—Currently Amended) A method of modulating the homotypic and/or heterotypic adhesion of CD66 family members or adhesion of a CD66 protein to a CD66 ligand; the method comprising contacting CD66 family members and/or their ligands with the isolated peptide of claim 1 at least one peptide or peptide conjugate comprising an amino acid sequence represented by SEQ ID NOs:7 15, 17, 22, 32, 33, 35, 37, 39, 47, 53, 54, or analogs thereof.

20. (Withdrawn—Currently Amended) The method of claim 19 wherein the peptide is represented by SEQ ID NO[[s]]: 14 [[7-15, 17, 22, 32, 33, 35, 37, 39, 47, 53, or 54]].

21. (Withdrawn) The method of claim 19 which is carried out *in vitro*.

22. (Withdrawn) The method of claim 19 which is carried out *in vivo*.

23-26. (Canceled)

27. (Currently Amended) A method of modulating immune cell activation, proliferation, and/or differentiation; the method comprising contacting an immune cell with at least one peptide or peptide conjugate comprising an amino acid sequence represented by SEQ ID NO[[s]]:14[[, 53,]] or a biologically active analog[[s]] thereof that decreases homotypic adhesion among CD66a family members.

28. (Currently Amended) The method of claim 27 wherein the peptide is represented by SEQ ID NO[[s]]:14 [[or 53]].

29. (Previously presented) The method of claim 27 wherein the immune cell is selected from the group of a T-cells, a B-cell, a LAK cell, an NK cell, a dendritic cell, and combinations thereof.

30. (Previously presented) The method of claim 27 which is carried out *in vitro*.

31. (Previously presented) The method of claim 27 which is carried out *in vivo*.

32-45. (Canceled)